Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
A phase 2 trial of AZD0486 in hodgkin lymphoma and non-hodgkin lymphoma, run by AstraZeneca, now recruiting.
Overview
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL is a phase 2 interventional study registered as NCT06526793 by AstraZeneca, with 270 participants planned, started 2024-11-27 and due to reach its primary completion in 2028-04-21. Interventions recorded: Surovatamig. Conditions listed: B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Shares AZD0486, Follicular lymphoma, AstraZeneca.
- TrialAZD0486 1L Therapy for Elderly or Unfit Participants With LBCL
Shares AZD0486, AstraZeneca.
- TrialSurovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin He
Shares AZD0486, AstraZeneca.
- TrialA Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Shares AZD0486, Non-Hodgkin lymphoma (all types), Hodgkin lymphoma, AstraZeneca.
- TrialA Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphom
Shares Non-Hodgkin lymphoma (all types), Hodgkin lymphoma, AstraZeneca.
- TrialA Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
Shares Follicular lymphoma, Non-Hodgkin lymphoma (all types), Hodgkin lymphoma.
- TrialAZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
Shares Non-Hodgkin lymphoma (all types), Hodgkin lymphoma, AstraZeneca.
- TrialStudy of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
Shares Non-Hodgkin lymphoma (all types), Hodgkin lymphoma, AstraZeneca.